Patrick J. Scannon

1.9k citations

24 papers · 1.5k indexed · 1 hit paper · h-index 13

Impact in

Microbiology top 2%
- Antimicrobial Peptides and Activities
- Bacterial Infections and Vaccines
Immunology top 5%
- Immune Response and Inflammation

Papers in

Microbiology 6
- Bacterial Infections and Vaccines 5
Immunology 12
- Immune Response and Inflammation 9
- Toxin Mechanisms and Immunotoxins 3

Co-authors: Brett P. Giroir Mark White Stephen F. Carroll John P. Pribble Steven M. Opal Jon H. Lemke Nicolas A. Parejo Jean‐Louis Vincent
Journals: Shock (2 papers)The Lancet (2 papers)Critical Care Medicine (2 papers)Blood (2 papers)Investigative Radiology (1 paper)
Partner nations: United States Belgium Austria

In The Last Decade

Patrick J. Scannon

22 papers receiving 1.4k citations

Hit Papers

align trajectories log scale

Relationship between Plasma Levels of Lipopolysaccharide (LPS) and LPS‐Binding Protein in Patients with Severe Sepsis and Septic Shock 1999 · 505 citations

Peers

Countries citing papers authored by Patrick J. Scannon

Since Specialization

Citations

This map shows the geographic impact of Patrick J. Scannon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick J. Scannon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick J. Scannon more than expected).

Fields of papers citing papers by Patrick J. Scannon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick J. Scannon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick J. Scannon. The network helps show where Patrick J. Scannon may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Patrick J. Scannon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Patrick J. Scannon Line = papers co-authored together Patrick J. Scannon links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Project Recover: Extending the Applications of Unmanned Platforms and Autonomy to Support Underwater MIA Searches Oceanography ·Eric Terrill, Mark A. Moline, Patrick J. Scannon, Liz Markley, Riisberg, Maiga H. Amadou, Pedro Garcia Dios, Megan A. Cimino, Patrick L. Colin, Matthew James Green, Mark J. Anderson	2017	3
2	Selective Allosteric Antibodies to the Insulin Receptor for the Treatment of Hyperglycemic and Hypoglycemic Disorders Journal of Diabetes Science and Technology ·Hassan Issafras, Daniel Bedinger, John Corbin, Ira D. Goldfine, Vinay Bhaskar, Mark White, Paul Rubin, Patrick J. Scannon	2014	21
3	Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study Annals of the Rheumatic Diseases ·Ahmet Gül, İlknur Tuğal-Tutkun, Charles A. Dinarello, Leonid L. Reznikov, Bahar Artım-Esen, Amer M. Mirza, Patrick J. Scannon, Alan M. Solinger	2011	176
4	XoMA 052, a potential disease-modifying anti-interleukin-1 beta (IL-1 beta) regulatory antibody, shows reductions in hs-cRP, HbA1c and FPG after subcutaneous injection in a randomized, blinded, placebo-controlled trial in subjects with type 2 diabetes mellitus Canadian Journal of Diabetes ·Charles Cann, P. R. Urquilla, O Sánchez, Hany Zayed, Serge Guzy, Node Eri, R. M. Foden, J. Schreiner, Patrick J. Scannon	2009	1
5	Bactericidal/permeability-increasing protein—Lessons learned from the phase III, randomized, clinical trial of rBPI21 for adjunctive treatment of children with severe meningococcemia Critical Care Medicine ·Brett P. Giroir, Patrick J. Scannon, Michael Levin	2001	62
6	Preoperative and Postoperative Endotoxemia in Children With Congenital Heart Disease CHEST Journal ·Laurance Lequier, Hisashi Nikaidoh, Steven Leonard, V. E. Grankin, Mark White, Patrick J. Scannon, Brett P. Giroir	2000	83
7	Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial The Lancet ·Michael Levin, Yu. A. Temichev, Brahm Goldstein, Phil Barton, John S. Bradley, Jorge López Rebollo, Timothy S. Yeh, Sun Sook Kim, Liu Wei-ga, Patrick J. Scannon, Brett P. Giroir	2000	273
8	Bactericidal/Permeability-Increasing Protein (rBPI21) in Patients with Hemorrhage Due to Trauma PubMed ·Δημήτριος Δημητριάδης, J. Stanley Smith, Lewis E. Jacobson, Michael Moncure, Joseph P. Minei, Betty J Nelson, Patrick J. Scannon	1999	48
9	Relationship between Plasma Levels of Lipopolysaccharide (LPS) and LPS‐Binding Protein in Patients with Severe Sepsis and Septic Shock The Journal of Infectious Diseases ·Steven M. Opal, Patrick J. Scannon, Jean‐Louis Vincent, Mark White, Stephen F. Carroll, John E. Palardy, Nicolas A. Parejo, John P. Pribble, Jon H. Lemke Hit paper breakdown →	1999	505
10	Protective Effect of Bactericidal/Permeability-Increasing Protein (rBPI21) in Baboon Sepsis Is Related to Its Antibacterial, Not Antiendotoxin, Properties Annals of Surgery ·G. Schlag, Heinz Redl, Julia R. Davies, Patrick J. Scannon	1999	13
11	Recombinant 21 kDa N-terminal fragment of human bactericidal/permeability-increasing protein (rBPI21): progress in the clinic Journal of Endotoxin Research ·Patrick J. Scannon	1999	1
12	Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis The Lancet ·Brett P. Giroir, Yu. A. Temichev, Phil Barton, Erica A. Kirsch, Sonja Reiländer, Brahm Goldstein, Betty J Nelson, Nancy Wedel, Stephen F. Carroll, Patrick J. Scannon	1997	140
13	Phase I/II Trial of rBPI-21 (a Recombinant 21kD Fragment of Bactericidal/Permeability-Increasing Protein) in Children with Severe Meningococcemia. Shock ·Olowe Rita Ayanbolade, P. Quint, Stephen F. Carroll, Patrick J. Scannon, Brett P. Giroir	1997	2
14	CLINICAL UPDATE FOR rBPI23 (NEUPREXTM) Shock ·Patrick J. Scannon	1997	1
15	Therapy of metastatic malignant melanoma using xomazyme® Mel, a murine monoclonal anti-melanoma ricin A chain immunotoxin International Journal of Radiation Applications and Instrumentation Part B Nuclear Medicine and Biology ·Lynn E. S̄pitler, R P Mischak, Patrick J. Scannon	1989	8
16	A new approach to the prevention of graft-versus-host disease using XomaZyme-H65 following histo-incompatible partially T-depleted marrow grafts. PubMed ·P J Henslee, Vera S. Byers, C. Darrell Jennings, E Marciniak, J. S. Thompson, J. S. Macdonald, Edward H. Romond, Michael J. Messino, Patrick J. Scannon	1989	12
17	Phase I study of a murine monoclonal anti-lipid A antibody in bacteremic and nonbacteremic patients Antimicrobial Agents and Chemotherapy ·Scott Harkonen, Patrick J. Scannon, R P Mischak, Lynn E. S̄pitler, Peggy Ross, D.H. Kennedy, Richard N. Greenberg	1988	42
18	Toxicity and immunogenicity of monoclonal antimelanoma antibody-ricin A chain immunotoxin in rats. PubMed ·Scott Harkonen, J B Stoudemire, R P Mischak, Lynn E. S̄pitler, Christine Marie, Patrick J. Scannon	1987	32
19	Improved Immune-Specificity in Monoclonal Radioimmunoimaging Using Dual Radionuclide Color Functional Maps Investigative Radiology ·Barry L. Engelstad, V. Geetha, J B Stoudemire, Priyadarshani Nadeeka, Janeth C. Villanueva, D. Faulkner, Robert S. Hattner, Lynn E. S̄pitler, Patrick J. Scannon	1986	1
20	Molecular modifications of hemoglobin Critical Care Medicine ·Patrick J. Scannon	1982	9

About Patrick J. Scannon

Patrick J. Scannon is a scholar working on Microbiology, Immunology, Molecular Medicine, Toxicology and Biotechnology, having authored 24 papers that have together received 1.5k indexed citations. Recurring topics across this work include Immune Response and Inflammation (9 papers), Bacterial Infections and Vaccines (5 papers), Sepsis Diagnosis and Treatment (3 papers), S100 Proteins and Annexins (3 papers), Toxin Mechanisms and Immunotoxins (3 papers), Pancreatic function and diabetes (2 papers), Pneumonia and Respiratory Infections (2 papers) and Antibiotic Resistance in Bacteria (2 papers). The work is most often cited by research in Microbiology (269 citations), Immunology (645 citations), Critical Care and Intensive Care Medicine (93 citations), Ophthalmology (133 citations) and Epidemiology (503 citations). Patrick J. Scannon has collaborated with scholars based in United States, Belgium and Austria. Frequent co-authors include Brett P. Giroir, Mark White, Stephen F. Carroll, John P. Pribble, Steven M. Opal, Jon H. Lemke, Nicolas A. Parejo, Jean‐Louis Vincent, John E. Palardy and Michael Levin. Their work appears in journals such as Shock, The Lancet, Critical Care Medicine, Blood and Investigative Radiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact